Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
A Phase 1 open-label, non-randomized dose escalation study to determine the maximum tolerated
dose (MTD) and characterize the safety and tolerability of Birinapant (TL32711).